BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 11, 2025
Home » Newsletters » BioWorld

BioWorld

Jan. 17, 2014

View Archived Issues

Pharma: Other news to note

Alvogen Pharma U.S., of Pinebrook, N.J., agreed in December 2013 to become the majority shareholder in Lotus Pharmaceutical Co. Ltd., of Taipei, through a private placement of newly issued shares, acquiring up to 151 million shares in the company. Read More

Clinic roundup

Biothera Inc., of Eagan, Minn., reported the results of its Phase II trial evaluating the effectiveness of Imprime PGG in combination with Erbitux (cetuximab), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapies alone in previously untreated patients with advanced non-small-cell lung cancer. Read More

Other news to note

Plandai Biotechnology Inc., of Seattle, said it entered a deal with cannabis grower Diego Pellicer Inc. and Diego Pellicer Worldwide Inc., to permit the company to use the Diego Pellicer name for its Phytofare cannabis extracts in medical and pharmaceutical marijuana applications. Read More

Holiday notice

BioWorld’s offices will be closed Monday, Jan. 20, in observance of the Martin Luther King Day holiday in the U.S. Read More

Stock Movers

Read More

Financings roundup

Bio-Path Holdings Inc., of Houston, said it is raising about $10 million in a registered direct offering at a price of $3 per unit, with each unit consisting of one share of common stock and a warrant to purchase one half of a share. Read More

From both sides now: Calistoga ex-CEO ventures into Frazier

SAN FRANCISCO – On the first morning of the 32nd Annual J.P. Morgan (JPM) Healthcare Conference, Carol Gallagher, unlike almost everyone else in JPM’s orbit, seemed calm, quiet and reflective. Read More

New drug discovery initiatives get under way in Germany

Two unconnected drug discovery initiatives unveiled on Wednesday provide further evidence of Germany’s ongoing strengths in the chemical and biological disciplines underpinning modern drug discovery, notwithstanding an ongoing lack of confidence in the area on the part of the country’s investors. Read More

Avillion’s co-development model draws Pfizer into first deal

LONDON – After a year of spreading the word and working to convince people of the attractions of its finance and risk-sharing model, Avillion Group Partners LLP has signed up Pfizer Inc. as the first partner for its Phase III co-development scheme. Read More

Intrexon’s Kirk talks big picture in future of synthetic biology

SAN FRANCISCO – Months after its initial public offering (IPO), Intrexon Corp. inked a string of exclusive channel collaborations (ECC) with biotechs of different shapes and sizes. Read More

Appointments and advancements

Isto Technologies Inc., of St. Louis, appointed George W. Dunbar Jr. president and CEO. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 10, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Brenig Therapeutics discovers new LRRK2 inhibitors

    BioWorld Science
    Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing